SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.20% Stake in Cyclacel Pharmaceuticals

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 9.20% of Cyclacel Pharmaceuticals, Inc.'s common stock as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons,' have filed an Amendment No. 2 to Schedule 13G.
• The filing indicates shared beneficial ownership of 24,844,725 shares of Cyclacel Pharmaceuticals, Inc. common stock.
• This ownership represents 9.20% of the total outstanding common stock of Cyclacel Pharmaceuticals, Inc.
• The shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC acts as the investment manager, and Steven Boyd is the managing member of Armistice Capital, LLC.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the issuer's performance or prospects. The sentiment is neutral as it's a standard regulatory filing.

Positives

• A significant institutional investor, Armistice Capital, LLC, and its managing member, Steven Boyd, have taken a substantial stake in Cyclacel Pharmaceuticals, Inc., potentially signaling confidence in the company's long-term prospects.
• The filing explicitly states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control, which can provide stability and reduce concerns about activist investor intervention.

Negatives

• The document is a standard beneficial ownership disclosure and does not contain information regarding the company's operational performance, financial health, or strategic challenges, thus offering no direct negative insights from the issuer's perspective.

Risks

• The document itself does not detail risks specific to Cyclacel Pharmaceuticals, Inc.'s operations or financial condition.
• The Reporting Persons certify that their acquisition and holding of shares are not for the purpose of changing or influencing control of the issuer, mitigating a potential risk of hostile takeover attempts or disruptive activist campaigns from this specific shareholder.

Management Comments

• Steven Boyd, as Managing Member of Armistice Capital, LLC, and in his individual capacity, certified that 'to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.'

Industry Context

This Schedule 13G filing indicates a significant passive investment by Armistice Capital, LLC and Steven Boyd in Cyclacel Pharmaceuticals, Inc., a company likely operating in the biotechnology or pharmaceutical sector. Such filings are common for institutional investors accumulating a stake above 5% and typically signal a long-term, non-activist position. For a biotech company, a substantial institutional holding can be viewed positively as it suggests investor confidence, which is crucial for companies often reliant on capital raises and clinical trial successes.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder can provide a sense of validation and potentially attract further investor interest. It also clarifies that this specific large holder is not seeking to influence control, which can reduce uncertainty.
• Company Management: Awareness of a large, passive institutional holder can influence management's strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

Cyclacel Pharmaceuticals, Armistice Capital, Steven Boyd, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investment, biotechnology, pharmaceuticals